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1. BACKGROUND {#ppul24855-sec-0010}
=============

In December 2019, a number of viral pneumonia was reported in China. It was later named by the WHO as COVID‐19 and the causative agent was named as SARS‐CoV‐2. The first case of COVID‐19 was reported in Hubei province, China, about 1000 km north of Guangdong province, the origin of SARS. Although geographical relevance may not play a role in the evolution of the virus, it has been hypothesized that SARS‐CoV and SARS‐CoV‐2 share similar pathogenesis and epidemiology due to genetic similarity between the two.[^1^](#ppul24855-bib-0001){ref-type="ref"}, [^2^](#ppul24855-bib-0002){ref-type="ref"} For instance, fever was observed in about 99% of patients infected with SARS‐CoV[^3^](#ppul24855-bib-0003){ref-type="ref"} and SARS‐CoV‐2.[^4^](#ppul24855-bib-0004){ref-type="ref"}

Like SARS‐CoV, SARS‐CoV‐2 is one of the seven human coronaviruses, a group of viruses of Alphacoronavirus and Betacoronavirus genera. While it is associated with higher mortality compared with the common cold‐related strains NL63, OC43, HKU1, and 229E as well as SARS‐CoV,[^5^](#ppul24855-bib-0005){ref-type="ref"} it also caused the largest outbreak of human coronavirus up to date, more prevalent than SARS‐CoV. Consequently, it has been suggested that the basic reproductive number (R~0~) of SARS‐CoV‐2 was higher compared to SARS‐CoV.[^6^](#ppul24855-bib-0006){ref-type="ref"}

Partly because of the lack of available clinical data, clinical features of SARS‐CoV‐2 infections in children remain little known. For instance, it is not clear if they are more susceptible to SARS‐CoV‐2 and if the clinical presentation differs in children compared with adults.[^7^](#ppul24855-bib-0007){ref-type="ref"} Against this background, the present study aims to clarify the clinical features of COVID‐19 in children.

2. METHODS {#ppul24855-sec-0020}
==========

As a comparative study, both adults and children were considered. A child was defined as a patient of age below 18. As of 17 April 2020, there are still no confirmed sources regarding deaths in pediatric patients with COVID‐19 in China but the United States, the United Kingdom, and the Philippines. Moreover, it was suggested that advanced age was associated with deaths.[^8^](#ppul24855-bib-0008){ref-type="ref"} To reduce the systematic bias driven by the difference in the clinical features between surviving and deceased adult patients, the present study considered discharged patients with COVID‐19.

As most of the cases were reported by the media rather than by the local health authorities in China, a few searches were performed on Google between 13 February 2020 and 17 April 2020 with search terms "pneumonia" AND "novel coronavirus" AND "age" AND "discharge" in Chinese.

The following data were abstracted: (a) travel history to Hubei, (b) gender, (c) age, (d) time from symptom onset to hospital admission, (e) time from hospital admission to discharge, and (f) symptoms on admission.

An individual case was included if all following inclusion criteria were met: (a) the patient was infected with SARS‐CoV‐2, (b) the exact age of the patient was stated, (c) the date of discharge was stated, and (d) symptoms on admission were stated. There was no language restriction.

All statistical tests and estimation were performed on the abstracted data by R software. To investigate any significant difference in the central tendency measure between children and adults, the Student *t* tests and the Mann‐Whitney tests were performed on interval data, such as time from hospital admission to discharge, whereas z‐tests were performed on nominal data, such as symptoms on admission. To take into account possible confounding relationships, adjusted odds ratio (OR) were estimated using logistic regression with the stepwise regression procedure for independent variable selection.[^9^](#ppul24855-bib-0009){ref-type="ref"}

3. RESULTS {#ppul24855-sec-0030}
==========

A total of 451 patients in 22 provinces, municipalities, and autonomous regions from 122 sources were included for study. Data granularity varied greatly among provinces. For example, symptoms were commonly reported in Shanghai whereas they were usually disregarded in Hubei.

Table [1](#ppul24855-tbl-0001){ref-type="table"} shows the summary statistics about the two groups. The minimum and maximum age of the patients included in the study were 9 hours and 96 years, respectively. Children accounted for 9.5% (95% CI, 7.0‐12.6) of all patients. Figure [1](#ppul24855-fig-0001){ref-type="fig"} (left panel) graphically illustrates the cumulative relative frequency of the age of patients in this study as well as the general Chinese population.[^10^](#ppul24855-bib-0010){ref-type="ref"} The difference in the cumulative relative frequency between the two groups widened until the group "Age 29 or below" (gray solid line). The difference started to narrow after, suggesting a more prominent infection of SARS‐CoV‐2 in patients of age above 29.

###### 

Patients' characteristics and symptoms on admission

                                                                                                            Age below 18 (n)   Age 18 or above (n)   *P*‐value[\*](#ppul24855-tbl1-note-0003){ref-type="fn"}   Adjusted OR (children/adult)
  ----------------------------------------------------------------------------------------------- --------- ------------------ --------------------- --------------------------------------------------------- ------------------------------
  Age (min, max; y)                                                                                         9 h,17 (43)        18,96 (408)                                                                     
  Male                                                                                                      51.3% (20/39)      53.1% (215/405)       .962                                                      
  Travel history to Hubei                                                                                   45.0% (18/40)      56.0% (216/386)       .246                                                      
  Median time from symptom onset to admission[^a^](#ppul24855-tbl1-note-0002){ref-type="fn"}, d             1.0 (16)           3.0 (79)              .248                                                      
  Median time from admission to discharge[^a^](#ppul24855-tbl1-note-0002){ref-type="fn"}, d                 16.0 (27)          15.0 (131)            .710                                                      
  Number of symptoms[^a^](#ppul24855-tbl1-note-0002){ref-type="fn"}                               Median    1.0 (41)           1.0 (385)             .164                                                      0.51 (0.27,0.97)
  Mean                                                                                            1.3(41)   1.5(385)           .039                                                                            
  Abdominal pain/discomfort                                                                                 0.0% (0/40)        0.8% (3/385)          1.000                                                     
  Anorexia                                                                                                  0.0% (0/40)        0.5% (2/385)          1.000                                                     
  Chest pain/discomfort                                                                                     2.5% (1/40)        3.6% (14/387)         1.000                                                     
  Chill                                                                                                     0.0% (0/40)        3.9% (15/388)         .415                                                      
  Cough                                                                                                     35.7% (15/42)      41.2% (164/398)       .600                                                      
  Diarrhea                                                                                                  5.0% (2/40)        1.3% (5/386)          .271                                                      
  Dizziness                                                                                                 0.0% (0/40)        1.3% (5/386)          1.000                                                     
  Dyspnea                                                                                                   2.5% (1/40)        3.9% (15/387)         1.000                                                     
  Fever                                                                                                     67.4% (29/43)      82.9% (334/403)       .023                                                      0.50 (0.24,1.05)
  Headache                                                                                                  0.0% (0/40)        2.8% (11/386)         .577                                                      
  Lethargy                                                                                                  2.5% (1/40)        9.9% (39/392)         .207                                                      
  Myalgia                                                                                                   2.4% (1/41)        3.3% (13/390)         1.000                                                     
  Nasal congestion/rhinorrhoea                                                                              9.8% (4/41)        1.0% (4/385)          .001                                                      16.44 (3.15,85.76)
  Sore throat                                                                                               7.3% (3/41)        3.9% (15/385)         .531                                                      
  Vomiting/nausea                                                                                           5.0% (2/40)        1.0% (4/387)          .186                                                      

Abbreviation: OR, odds ratio.

Data not normally distributed.

Rounded to 3 decimal places.
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There was no significant difference in the proportion of patients with travel history to Hubei between the children and the adult group. Similarly, there was no significant difference in the male proportion between the two groups. Given similar median time from symptom onset to admission between children and adults, the insignificant difference in the median time from symptom onset to admission suggested similar length of clinical course. Time from symptom onset to admission and time from admission to discharge were excluded by the stepwise regression procedure, suggestive of a possible correlation between the two variables.

A significant difference in the number of symptoms was also observed. Both the Student *t* test and Mann‐Whitney test concluded fewer symptoms in children. The fever remained the most commonly seen symptom followed by cough but was not significant between the two groups. Nasal congestion/rhinorrhoea was observed in nearly 10% of all children and was significantly more prominent than in adults. After taking into account possible confounding relationships, the 95% CI of the adjusted ORs suggested that nasal congestion/rhinorrhea was more commonly seen in children whereas cough was less prominent. However, no significant difference was observed in other symptoms. Although contradicting results were observed in the difference in the median and the mean of the number of symptoms, the 95% CI of the adjusted OR showed that children did have few symptoms than adults did.

4. DISCUSSION {#ppul24855-sec-0040}
=============

The present study clarifies the clinical characteristics of children with COVID‐19 using the clinical data reported by the media in China. A total of 451 patients including 43 patients of age below 18 were included in the study.

The data showed that patients of age below 30 were less susceptible to SARS‐CoV‐2 infection, as suggested by Figure [1](#ppul24855-fig-0001){ref-type="fig"} (left panel). This was slightly different from the case of SARS‐CoV where children of age below 18 were less susceptible. Figure [1](#ppul24855-fig-0001){ref-type="fig"} (right panel) was created using the data reported in a study that considered more than 5000 Chinese patients infected with SARS‐CoV between November 2002 and May 2003.[^11^](#ppul24855-bib-0011){ref-type="ref"} The figure graphically illustrates the cumulative relative frequency of age. SARS‐CoV infection was less prominent in patients of age 19 or below, as suggested by the difference in cumulative relative frequency (solid gray line) between the studied cohort (solid black line) and the Chinese population[^12^](#ppul24855-bib-0012){ref-type="ref"} (dashed line). With SARS‐CoV infection more prominent in patients of age above 19, the difference in cumulative relative frequency disappeared rapidly.

The shorter clinical course was observed in children with SARS, as evidenced by the similar average time from symptom onset to admission yet different average time from admission to discharge between age groups. The average time from symptom onset to admission was similar between different age groups, 4 days for patients age below 20 and between 3.1 and 4 days for other Chinese patients. The average time from admission to discharge for patients of age below 20 and other patients were 24.9 days and 26.5 to 30.9 days, respectively.[^11^](#ppul24855-bib-0011){ref-type="ref"} In contrast, our results failed to reach a similar conclusion in COVID‐19. No significant difference was found in the median time from symptom onset to admission and from admission to discharge.

However, SARS‐CoV and SARS‐CoV‐2 infection in children might be similar in other aspects. For instance, upper respiratory tract infection was more commonly seen in children with SARS, as evidenced by the absence of chest radiograph abnormalities.[^13^](#ppul24855-bib-0013){ref-type="ref"} Table [2](#ppul24855-tbl-0002){ref-type="table"} shows the comparison of clinical features between the two diseases in children from different studies.[^14^](#ppul24855-bib-0014){ref-type="ref"}, [^15^](#ppul24855-bib-0015){ref-type="ref"}, [^16^](#ppul24855-bib-0016){ref-type="ref"}, [^17^](#ppul24855-bib-0017){ref-type="ref"}, [^18^](#ppul24855-bib-0018){ref-type="ref"}, [^19^](#ppul24855-bib-0019){ref-type="ref"}, [^20^](#ppul24855-bib-0020){ref-type="ref"}, [^21^](#ppul24855-bib-0021){ref-type="ref"} While fever and cough remained the most prominent symptoms, relatively low prevalence in chest pain/discomfort, and dyspnea was observed in both diseases, suggestive of less common lower respiratory tract infection in children. In addition, patients with nasal congestion/rhinorrhoea were 16 times more likely to be children while patients with cough were two times more likely to be adults, as shown in Table [1](#ppul24855-tbl-0001){ref-type="table"}.

###### 

Comparison of clinical features between SARS‐CoV and SARS‐CoV‐2 in children of age below 18, unless stated otherwise

                                 SARS‐CoV    SARS‐CoV‐2                                                                                                                                                                                                                                                          
  ------------------------------ ----------- ------------ ---------------------------------------------------- ------------------------------------------------------ ---------------- ----------------------------------------------------- ---------------------------------------------------- -------------- --------------
  Infection                                                                                                                                                                                                                                                                                                      
  Sample size                    64          47           62                                                   43                                                     10               14                                                    171                                                  9              10
  Median (mean) age, years       11.7 (12)   13.6 (N/A)   N/A (6.8)                                            4.0 (5.7)                                              9.5 (9.2)        6.2 (N/A)                                             6.7 (N/A)                                            8 (7.6)        8.8 (7.6)
  Male to female ratio           29:35       26:21        30:32                                                20:19[^b^](#ppul24855-tbl2-note-0002){ref-type="fn"}   5:5              6:8                                                   104:67                                               3:6            3:7
  Location                       Hong Kong   Hong Kong    Toronto, Singapore, Hong Kong                        China                                                  Jiangsu, China   Shandong, China                                       Wuhan, China                                         Hunan, China   Hunan, China
  Symptom, %                                                                                                                                                                                                                                                                                                     
  Abdominal pain/discomfort      6.3         1.3          N/A                                                  0.0                                                    N/A              0.0                                                   N/A                                                  0.0            10.0
  Anorexia                       23.4        21.8         0.0                                                  0.0                                                    N/A              0.0                                                   N/A                                                  0.0            N/A
  Chest pain/discomfort          1.6         0.0          0.0                                                  2.5                                                    N/A              0.0                                                   N/A                                                  0.0            N/A
  Chill                          32.8        40.0         14.5                                                 0.0                                                    N/A              N/A                                                   N/A                                                  0.0            N/A
  Cough                          56.3        56.4         62.9                                                 35.7                                                   30.0             21.4[^c^](#ppul24855-tbl2-note-0003){ref-type="fn"}   48.5                                                 11.1           30.0
  Diarrhea                       17.2        23.6         9.7[^a^](#ppul24855-tbl2-note-0001){ref-type="fn"}   5.0                                                    0.0              0.0                                                   8.8                                                  22.2           N/A
  Dizziness                      18.8        18.2         0.0                                                  0.0                                                    N/A              0.0                                                   N/A                                                  0.0            N/A
  Dyspnea                        9.4         1.3          0.0                                                  2.5                                                    0.0              0.0                                                   N/A                                                  0.0            N/A
  Fever                          96.9        98.0         100.0                                                67.4                                                   40.0             35.7                                                  41.5                                                 44.4           30.0
  Headache                       28.1        0.0          11.3                                                 0.0                                                    20.0             7.1                                                   N/A                                                  0.0            N/A
  Lethargy                       4.7         0.0          6.5                                                  2.5                                                    N/A              7.1                                                   7.6                                                  0.0            N/A
  Myalgia                        28.1        29.1         17.7                                                 2.4                                                    N/A              7.1                                                   N/A                                                  0.0            N/A
  Nasal congestion/rhinorrhoea   40.6        31.0         22.6                                                 9.8                                                    N/A              N/A                                                   5.3/7.6                                              0.0            N/A
  Sore throat                    10.9        11.0         9.7                                                  7.3                                                    0.0              N/A                                                   N/A                                                  11.1           N/A
  Vomiting/nausea                20.3        12.7         9.7[^a^](#ppul24855-tbl2-note-0001){ref-type="fn"}   5.0                                                    0.0              0.0                                                   6.4[^d^](#ppul24855-tbl2-note-0004){ref-type="fn"}   0.0            10.0

Gastrointestinal symptoms.

Gender of four patients not known.

Dry cough.

Vomiting only.
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It is also important to note that nonspecific symptoms such as anorexia, dizziness, abdominal pain/discomfort, and headache were observed in children with SARS. It is possible that these nonspecific symptoms may also be observed in children with COVID‐19. In particular, gastrointestinal symptoms in patients with COVID‐19 may imply the route of infection. A study in SARS‐related diarrhea found that patients infected via the fecal‐oral route were more likely to develop diarrhea.[^22^](#ppul24855-bib-0022){ref-type="ref"} If COVID‐19 shares a similar aetiopathogenesis, the varying prevalence of diarrhea in children with COVID‐19 between 0% to 22%, as shown in Table [2](#ppul24855-tbl-0002){ref-type="table"}, might be explained by fecal‐oral transmission. As a respiratory disease, COVID‐19 is predominately transmitted via respiratory droplets and hence respiratory tract symptoms were commonly observed in patients. By the same token, the incidental fecal‐oral transmission of COVID‐19 should see different prevalence rates of gastrointestinal symptoms in different clinical studies.

Another similarity between SARS and COVID‐19 in children is that younger children had a less aggressive clinical course, compared with adolescents. This finding in SARS has been well documented.[^23^](#ppul24855-bib-0023){ref-type="ref"}, [^24^](#ppul24855-bib-0024){ref-type="ref"} For instance, symptoms such as chills, rigor, and myalgia were more common in adolescents yet rare in younger children with SARS.[^25^](#ppul24855-bib-0025){ref-type="ref"} As shown in Table [2](#ppul24855-tbl-0002){ref-type="table"}, chill, dizziness, and myalgia were less commonly observed in Babyn et al[^16^](#ppul24855-bib-0016){ref-type="ref"} where the studied cohort comprised of younger children with an average age of 6.8 years. In contrast, these symptoms were shown more prevalent in Leung and Chiu[^14^](#ppul24855-bib-0014){ref-type="ref"} and Li et al[^15^](#ppul24855-bib-0015){ref-type="ref"} where the studied cohorts had a median age of 11.7 and 13.6 years, respectively. The cohort in the present study comprised of younger children with a median age of 4 years. Chill and dizziness were not observed while myalgia was observed in only 2.4% of patients of age below 18 years. In another two clinical studies concerning children infected with SARS‐CoV‐2, chill and dizziness were not observed whereas myalgia was seen in 0% to 7.1% of the children.[^18^](#ppul24855-bib-0018){ref-type="ref"}, [^20^](#ppul24855-bib-0020){ref-type="ref"}

The mechanism behind the reduced susceptibility in children remains an active area for research. A number of studies have aimed to understand the pathogenesis by considering the association between age‐related susceptibility to COVID‐19 and angiotensin‐converting enzyme 2 (ACE2), a negative regular of the renin‐angiotensin system (RAS) that was found to mediate the host cell entry of SARS‐CoV and SARS‐CoV‐2. However, contradicting findings have been observed. For example, expression of ACE2 was found higher in Asian females yet lowered during aging[^26^](#ppul24855-bib-0026){ref-type="ref"} whereas another study found that increased expression was associated with age yet not with gender.[^27^](#ppul24855-bib-0027){ref-type="ref"} Similarly, a study found increased expression of ACE2 with age in females as well as higher expression in males compared to females.[^28^](#ppul24855-bib-0028){ref-type="ref"} However, this finding failed to explain the lower prevalence of SARS observed in men, 46% (n = 483) in Taiwan,[^29^](#ppul24855-bib-0029){ref-type="ref"} 44% (n = 1755) in Hong Kong,[^30^](#ppul24855-bib-0030){ref-type="ref"} and 34% (n = 201) in Singapore.[^31^](#ppul24855-bib-0031){ref-type="ref"} The opposite view has also been proposed. For instance, it has been suggested that ACE2 produced the heptapeptide angiotensin (1‐7), the abundant peptide of the RAS, which had favorable effects on the pulmonary endothelial cells and might provide resilience from the development of pulmonary failure in COVID‐19.[^32^](#ppul24855-bib-0032){ref-type="ref"}

Another possible explanation is that children are less likely smokers. Recent studies suggested that higher levels of ACE2 expression was found in smokers[^33^](#ppul24855-bib-0033){ref-type="ref"}, [^34^](#ppul24855-bib-0034){ref-type="ref"} and after SARS‐CoV infection, suggestive of a role of postinfectious regulation.[^34^](#ppul24855-bib-0034){ref-type="ref"} The mechanism behind remains uncertain because nicotine was found to downregulate the expression of ACE2[^35^](#ppul24855-bib-0035){ref-type="ref"} and contradicting findings concerning the levels of ACE2 expression in individuals with chronic obstructive pulmonary disease.[^33^](#ppul24855-bib-0033){ref-type="ref"}, [^34^](#ppul24855-bib-0034){ref-type="ref"}

Finally, the hypothesized links between cytokine storm syndrome and mortality may also explain the reduced fatality risk of children with COVID‐19.[^36^](#ppul24855-bib-0036){ref-type="ref"}, [^37^](#ppul24855-bib-0037){ref-type="ref"} On one hand, a number of studies have proposed the association between aging and increased cytokine production, interferon‐γ (IFN‐γ) for example,[^38^](#ppul24855-bib-0038){ref-type="ref"}, [^39^](#ppul24855-bib-0039){ref-type="ref"} meaning that children are less susceptible to cytokine storm syndrome. On the other hand, a recent study found that SARS‐CoV‐2 generally triggered lower levels of cytokines, including IFN‐γ and IL‐12 (an interleukin induces the production of IFN‐γ[^40^](#ppul24855-bib-0040){ref-type="ref"}), compared to SARS‐CoV infection.[^41^](#ppul24855-bib-0041){ref-type="ref"} In addition, this study also suggested that SARS‐CoV‐2 was capable of infecting and replicating more robustly than SARS‐CoV in human lung tissues because the nucleocapsid antigens of SARS‐CoV‐2 were detected in higher abundance and in broader areas of human lung tissues than that of SARS‐CoV. Taken together, these findings might explain the less severity in children with COVID‐19, as demonstrated by a lower prevalence of cough, fever, and nasal congestion/rhinorrhoea compared to SARS, as shown in Table [2](#ppul24855-tbl-0002){ref-type="table"}.

This study has some limitations. The size of the children\'s cohort was small hence some symptoms such as headache and abdominal pain/discomfort were not observed. However, it was expected the prevalence of these symptoms to remain low since the sample in the study is sufficiently random to reduce any symptom‐related systematic bias. Comorbidities were not considered in the study as they were not reported by the media. Still, chronic diseases are uncommon in children.
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